Royal Bank of Canada Reaffirms “Outperform” Rating for Pyxis Oncology (NASDAQ:PYXS)

Royal Bank of Canada reiterated their outperform rating on shares of Pyxis Oncology (NASDAQ:PYXS) in a report released on Wednesday,Benzinga reports. Royal Bank of Canada currently has a $8.00 price target on the stock.

Several other analysts have also commented on PYXS. William Blair lowered shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 21st. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Pyxis Oncology in a report on Wednesday. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $9.20.

Pyxis Oncology Trading Up 8.0 %

Shares of PYXS opened at $1.21 on Wednesday. The stock has a fifty day moving average price of $1.33 and a 200-day moving average price of $2.36. Pyxis Oncology has a 12 month low of $0.99 and a 12 month high of $6.18. The firm has a market cap of $74.52 million, a PE ratio of -1.17 and a beta of 1.11.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.01. The business had revenue of $16.15 million for the quarter. As a group, research analysts forecast that Pyxis Oncology will post -1.04 EPS for the current year.

Institutional Investors Weigh In On Pyxis Oncology

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Jacobs Levy Equity Management Inc. purchased a new stake in Pyxis Oncology in the 3rd quarter valued at $1,405,000. Geode Capital Management LLC increased its holdings in shares of Pyxis Oncology by 5.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,084,727 shares of the company’s stock worth $3,982,000 after buying an additional 57,016 shares during the last quarter. Barclays PLC increased its holdings in shares of Pyxis Oncology by 275.0% during the 3rd quarter. Barclays PLC now owns 64,089 shares of the company’s stock worth $235,000 after buying an additional 46,997 shares during the last quarter. State Street Corp raised its position in shares of Pyxis Oncology by 28.0% during the 3rd quarter. State Street Corp now owns 951,251 shares of the company’s stock valued at $3,491,000 after buying an additional 208,344 shares during the period. Finally, Jane Street Group LLC lifted its holdings in Pyxis Oncology by 40.8% in the third quarter. Jane Street Group LLC now owns 49,558 shares of the company’s stock valued at $182,000 after acquiring an additional 14,349 shares during the last quarter. Institutional investors and hedge funds own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.